Citius Pharmaceuticals
CTXR
11 hedge funds and large institutions have $499K invested in Citius Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
38% more funds holding
Funds holding: 8 → 11 (+3)
0.13% less ownership
Funds ownership: 0.21% → 0.08% (-0.13%)
48% less capital invested
Capital invested by funds: $962K → $499K (-$463K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
+$99.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.3K |
| 4 |
Morgan Stanley
New York
|
+$24.7K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$768K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$29K |
| 3 |
Renaissance Technologies
New York
|
-$5.42K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$2.35K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $158K | +$67.1K | +2,280 | +106% |
|
|
BAAM
2
Baker Avenue Asset Management
San Francisco,
California
| $120K | +$99.9K | +3,395 | New |
|
|
3
Renaissance Technologies
New York
| $102K | -$5.42K | -184 | -6% |
|
|
4
Citadel Advisors
Miami,
Florida
| $38K | +$31.3K | +1,063 | New |
|
|
5
Morgan Stanley
New York
| $29K | +$24.7K | +840 | New |
|
6
Dimensional Fund Advisors
Austin,
Texas
| $20K | – | – | – |
|
|
RJA
7
Raymond James & Associates
St Petersburg,
Florida
| $17K | – | – | – |
|
|
8
Acadian Asset Management
Boston,
Massachusetts
| $10K | +$8.51K | +289 | New |
|
9
Wells Fargo
San Francisco,
California
| $3K | +$2.35K | +80 | New |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | -$2.35K | -80 | -67% |
|
|
HCM
11
Hilton Capital Management
Garden City,
New York
| $1K | +$795 | +27 | New |
|
|
AC
12
Armistice Capital
New York
| – | -$768K | -29,537 | Closed |
|
|
SM
13
Sabby Management
Miami Beach,
Florida
| – | -$29K | -1,122 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$1K | -27 | Closed |
|
CTXR Hedge Fund Activity: Q1 2019 in Review
11 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2019, worth a combined $499K — down 48% from $962K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CTXR positions and 3 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Baker Avenue Asset Management, opening a new position worth an estimated $99.9K. The largest seller was Armistice Capital, exiting entirely with an estimated $768K sold.
- 11 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2019, up from 8 in Q4 2018.
- Funds reported $499K of Citius Pharmaceuticals stock for Q1 2019, down 48% quarter-over-quarter.
- 6 funds opened new Citius Pharmaceuticals positions in Q1 2019 and 3 closed out, a net change of +3 holders.
- The largest Citius Pharmaceuticals buyer in Q1 2019 was Baker Avenue Asset Management, an estimated $99.9K added.
- The largest Citius Pharmaceuticals seller in Q1 2019 was Armistice Capital, an estimated $768K sold.
Based on aggregated 13F filings for Q1 2019.